Results 341 to 350 of about 304,614 (388)

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.

Arthritis & Rheumatism, 2007
OBJECTIVE Increased endothelin activity may play a role in the pathogenesis of vascular injury, a primary feature of systemic sclerosis (SSc; scleroderma).
P. Sfikakis, C. Papamichael, K. Stamatelopoulos, D. Tousoulis, K. Fragiadaki, P. Katsichti, C. Stefanadis, M. Mavrikakis   +7 more
semanticscholar   +1 more source

The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.

American Heart Journal, 2001
BACKGROUND Endothelin-1, a potent vasoconstrictor, is elevated in congestive heart failure and is postulated to play a major role in the pathogenesis of the disease. Endothelin receptor antagonism may be a specific therapeutic approach.
C. Schalcher, Gadi Cotter, L. Reisin, Osmund Bertel, I. Kobrin, Than-Tam Guyene, Wolfgang Kiowski   +6 more
semanticscholar   +1 more source

Update on Endothelin Receptor Antagonists in Hypertension

Current Hypertension Reports, 2018
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the treatment of hypertension and the management of diabetic nephropathy RECENT FINDINGS: Recent reviews and meta-analyses of experimental and clinical data obtained with ERAs confirmed that endothelin receptor blockade is associated with significant ...
openaire   +3 more sources

Endothelin receptor antagonists – their role in pulmonary medicine

Revue des Maladies Respiratoires, 2011
Understanding of the function of endothelin-1 in the pathophysiology of endothelial disease, in particular pulmonary arterial hypertension (PAH), has paved the way for the development of endothelin-receptor antagonists (ERAs) and explains the leading role they now play in the treatment armamentarium for this disease.Three active ERA drugs (bosentan ...
M. Reynaud-Gaubert, S. Boniface
openaire   +3 more sources

The Antagonists of Endothelin Receptors: Results and Perspectives

Current Pharmaceutical Analysis, 2005
In 1988 Yanagisawa described endothelins, a new class of vasoconstrictor agents produced by endothelial cells. Further biological effects of these peptides have subsequently been demonstrated, for example, induction of cell proliferation and fibrosis.
openaire   +3 more sources

Endothelin receptor antagonists for pulmonary arterial hypertension

2003
Pulmonary arterial hypertension (PAH) is a devastating disease, which leads to right heart failure and premature death. Pulmonary arterial hypertension can be classified into five categories according to Venice classification: (1) Idiopathic PAH; (2) Familial PAH; (3) PAH associated with collagen vascular disease, congenital systemic-to-pulmonary ...
C, Liu, J, Cheng
openaire   +3 more sources

Bosentan, a mixed endothelin receptor antagonist, inhibits superoxide anion-induced pain and inflammation in mice

Naunyn-Schmiedeberg's Archives of Pharmacology, 2015
K. G. Serafim, Suelen A. Navarro, Ana C Zarpelon, Felipe A. Pinho-Ribeiro, V. Fattori, T. Cunha, J. Alves-Filho, F. Cunha, R. Casagrande, W. Verri   +9 more
semanticscholar   +1 more source

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

The Lancet, 2001
R. Channick, G. Simonneau, O. Sitbon, I. Robbins, A. Frost, V. Tapson, D. Badesch, S. Roux, M. Rainisio, F. Bodin, L. Rubin   +10 more
semanticscholar   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog

Nature Structural &Molecular Biology, 2017
W. Shihoya, T. Nishizawa, K. Yamashita, A. Inoue, K. Hirata, Francois Marie Ngako Kadji, Akiko Okuta, K. Tani, J. Aoki, Y. Fujiyoshi, T. Doi, O. Nureki   +11 more
semanticscholar   +1 more source